Abstract 250P
Background
Treatment for cervical cancer can significantly affect a patient’s quality of life. The purpose of this research: to study the quality of life in patients with cervical cancer and to analyze the dependence of the quality of life indicators on radiation doses obtained when living in areas adjacent to the Semipalatinsk test site.
Methods
In this study, a survey was conducted of 20 patients (women aged 27 to 70 years, average age 52 years) who received chemoradiation therapy. The questionnaire to assess the quality of life, carried out after treatment, using the official versions of questionnaires EORTC QLQ-CX24. The QLQ-CX24 module includes functional and symptomatic scales. The assessment of individual radiation doses received while living in areas exposed to radioactive exposure was carried out in accordance with official guidelines.
Results
The results obtained for functional scales: overall quality of life 78.4 ± 15.2, body image 80.2 ± 15.3, sexual activity 20.4 ± 19.5, sexual satisfaction 52.4 ± 18.3, sexual/vaginal functioning 42.6 ± 19.8 points. For symptomatic scales: symptoms 15.6 ± 12.8, lymphadenoma 12.9 ± 15.4, peripheral neuropathy 23.9 ± 14.7, menopausal symptoms 33.3 ± 28.4, sexual anxiety 32.4 ± 22.5 points.
Individual radiation doses received by patients while living in radioactively contaminated territories range from 1.06 to 36.11 cSv. For the study group, the relationship between indicators of quality of life and individual radiation doses have not been established. It is impossible to unequivocally affirm the absence of this dependence due to the insufficient number and heterogeneity of the studied group in a number of parameters.
Conclusions
A sufficiently high scale value indicates the overall quality of life reflects a good level of functioning. The rather low levels of the scales of symptoms, lymphedema, peripheral neuropathy indicate the severity of this symptomatology during preventive exposure to PALS. For the study group, the relationship between indicators of quality of life and individual radiation doses have not been established.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
67TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Presenter: Norikazu Masuda
Session: e-Poster Display Session
68TiP - KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Presenter: Shigehira Saji
Session: e-Poster Display Session
69TiP - MADELINE Asia: A mobile app-based prospective observational study of patient reported outcomes in advanced breast cancer in Asia
Presenter: Anna Tai
Session: e-Poster Display Session
113TiP - Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan
Presenter: Hiroki Yukami
Session: e-Poster Display Session
195TiP - GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Rui-Hua Xu
Session: e-Poster Display Session
196TiP - Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Jia Wei
Session: e-Poster Display Session
197TiP - A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Presenter: Shukui Qin
Session: e-Poster Display Session
198TiP - SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Kohei Shitara
Session: e-Poster Display Session
233TiP - Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study
Presenter: Daniel Petrylak
Session: e-Poster Display Session
254TiP - ENGOT-cx11/KEYNOTE-A18: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab With Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer
Presenter: Domenica Lorusso
Session: e-Poster Display Session